Monocyte chemoattractant protein-1 is associated with silent cerebral infarction in patients on haemodialysis

Internal Medicine Journal

Volumn 42, Issue 1, 2012, Pages 29-34

  Uchida, E ^a,c   Anan, F ^b   Masaki, T ^c   Kaneda, K ^c   Nawata, T ^c   Eshima, N ^c   Saikawa, T ^c   Yoshimatsu, H ^c  

^a Tsukumi Central Hospital   (Japan)

^b Department of Cardiology   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

Haemodialysis; Monocyte chemoattractant protein 1; Silent cerebral infarction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRAIN INFARCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENDER; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INSULIN TREATMENT; JAPANESE; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SILENT BRAIN INFARCTION; SMOKING;

AGED; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CEREBRAL INFARCTION; CHEMOKINE CCL2; COMORBIDITY; FEMALE; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYPHARMACY; PREVALENCE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SMOKING;

EID: 84856240376     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02538.x     Document Type: Article

References (34)

1. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64: 603-9.
2. Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 1993; 44: 1086-90.
3. Iseki K, Fukuyama K. Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int 1996; 50: 1672-5.
4. Nakatani T, Naganuma T, Uchida J, Masuda C, Wada S, Sugimura T etal. Silent cerebral infarction in hemodialysis patients. Am J Nephrol 2003; 23: 86-90.
5. Naganuma T, Uchida J, Tsuchida K, Takemoto Y, Tatsumi S, Sugimura K etal. Silent cerebral infarction predicts vascular events in hemodialysis patients. Kidney Int 2005; 67: 2434-9.
6. Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MM. Kidney function is related to cerebral small vessel disease. Stroke 2008; 39: 55-61.
7. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46: 200-4.
8. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.
9. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophages infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-8.
10. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
11. Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999; 19: 91-104.
12. de Lemos JA, Morrow DA, Sanatine MS, Murphy SA, Gibson CM, Antman EM etal. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690-95.
13. Arakelyan A, Petrkova J, Hermanova Z, Boyajyan A, Lukl J, Petrek M. Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators Inflamm 2005; 3: 175-9.
14. Kusano KF, Nakamura K, Kusano H, Nishii N, Banba K, Ikeda T etal. Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J 2004; 68: 671-6.
15. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent cerebral infarction as a risk factor for clinical stroke. Stroke 1997; 28: 1932-9.
16. Fisher CM. Lacunar strokes and infarcts. Neurology 1982; 32: 871-6.
17. Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW etal. Multiple metabolic syndrome is associated with lower rate variability. Diabetes Care 1998; 21: 2116-22.
18. Anan F, Shimomura T, Kaku T, Kaneda K, Imagawa M, Tsukagawa H etal. High-sensitivity C-reactive protein is a significantly risk factor for silent cerebral infarction in patients on hemodialysis. Metabolism 2008; 57: 66-70.
19. Kohara K, Fujisawa M, Ando F, Tabara Y, Niino N, Miki T etal. MTHFR gene polymorphism as a risk factor for silent brain infracts and white matter lesions in the Japanese general population. The NILS-LSA study. Stroke 2003; 34: 1130-35.
20. Braffman BH, Zimmerman RA, Trojanowski JQ, Gonatas NK, Hickey WF, Schlaepfer WW. Pathologic correlation with gross and histopathology, 1: lacunar infarction and Virchow Robin spaces. Am J Roentgenol 1988; 151: 551-8.
21. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121-7.
22. Denger S, Jahn L, Wende P, Watson L, Gerber SH, Kübler W etal. Expression of Monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: induction of synthetic phenotype: a possible clue to SMC differentiation in the process of atherogenesis. Atherosclerosis 1999; 144: 15-23.
23. Watanabe T, Pakala R, Katagiri T, Benedict CR. Monocyte chemoattractant protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. J Vasc Res 2001; 38: 341-9.
24. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J 2002; 66: 529-33.
25. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF etal. Importance of Monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after attenuates atherosclerosis in apolipoprotein E-knockout mice and monkeys. Circ Res 2002; 90: 1167-72.
26. Hokimoto S, Oike Y, Saito T, Kitaoka M, Oshima S, Noda K etal. Increased expression of Monocyte chemoattractant protein-1 in atherectomy specimens from patients with restenosis after percutaneous transluminal coronary angioplasty. Circ J 2002; 66: 114-16.
27. Kim JS, Gautam SC, Chopp M, Zaloga C, Jones ML, Ward PA etal. Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat. J Neuroimmunol 1995; 56: 127-34.
28. Kirkham PA, Spooner G, Ffoulkes-Jones C, Calvez R. Cigarette smoking triggers macrophage adhesion and activation: role of lipid peroxidation products and scavenger receptor. Free Radic Biol Med 2003; 35: 697-710.
29. Yamaguchi Y, Matsuno S, Kagota S, Haginaka J, Kunitomo M. Oxidants in cigarette smoke extract modify low-density lipoprotein in the plasma and facilitate atherogenesis in the aorta of Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 2001; 156: 109-17.
30. Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol 2010; 31: 435-41.
31. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G etal. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atrovastatin treatment. Atrovastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Target Fast with Atrovastatin Stratified Titration. Am Heart J 2007; 153: 881-8.
32. Joner M, Farb A, Cheng Q, Finn AV, Acampado E, Burke AP etal. Pioglitazone inhibits in-stent restenosis atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 2007; 27: 182-9.
33. Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H etal. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am J Hypertens 2009; 22: 145-50.
34. Nyquist PA, Winkler CA, McKenzie LM, Yanek LR, Becker LC, Becker DM etal. Single nucleotide polymorphisms in monocyte chemoattractant protein-1 and its receptor act synergistically to increase the risk of carotid atherosclerosis. Cerebrovasc Dis 2009; 28: 124-30.